Wearable Biosensors
Wearable biosensors are analyzed by sensing target, including glucose, lactate, electrolytes, hydration and cardiac signals, and by form factor from patches to smart textiles. Clinical…
Multi-cancer early detection tests are covered by analyte and method, including cfDNA methylation, fragmentomics and protein panels. The report examines clinical validation, screening program pilots, reimbursement prospects and the laboratories bringing these blood tests to market.
The study gives estimates and forecasts for the global market and for each major region, with country-level analysis where the market warrants it. It profiles the companies that matter in this field and lists the wider supplier base in a corporate directory, together with recent product launches, partnerships, collaborations, mergers and acquisitions.
Strategists, investors, laboratories, contract research and manufacturing organizations, biotechnology and healthcare companies, academic professionals and regulatory teams use our reports to
The full table of contents and list of exhibits come with the sample pages. Request sample pages.
Reports are delivered as a PDF by email within one working day of payment. Payment by invoice. Read the license terms and terms of sale.
Ask for sample pages, a formal quotation for your purchasing team, or put a question to the analyst. Sample pages are sent to organization email addresses only.
Wearable biosensors are analyzed by sensing target, including glucose, lactate, electrolytes, hydration and cardiac signals, and by form factor from patches to smart textiles. Clinical…
Liquid biopsy is studied by analyte, including circulating tumor DNA, circulating tumor cells, exosomes and cell-free RNA, and by clinical use from screening to therapy selection and…
Digital pathology is examined across whole-slide scanners, image management systems, analysis algorithms and storage infrastructure. The report covers clinical diagnosis, research and…
Theranostics is reviewed as the pairing of diagnostic imaging with targeted radioligand therapy, with prostate and neuroendocrine cancers leading. The study covers radiopharmaceuticals…